See other companies on Welcome to the Jungle
Nephrosant
Diagnostic tools for kidney health
- 21-100 employees
- Healthcare
- B2B
- Personal health
- SaaS
- Science
- MedTech
- Beresford Park, San Mateo, CA
Jump to section
Company mission
To deliver new diagnostic tools for early detection and lifetime monitoring of kidney health and injury.
71% employee growth in 12 months
Our take
Chronic kidney disease affects more than 10% of the world’s adult population, and in the United States more than a quarter of every dollar spent by Medicare is used for some form of kidney disease.
NephroSant is a biotechnology company that puts its entire focus into predicting and preventing the progression of kidney disease. It’s offering is known as QSant – a needle-free urine test that allows for comprehensive assessment of kidney health. This prevents invasive biopsies, while still being able to determine whether acute rejection of a kidney transplant is likely.
A game-changer for many patients – besides being needleless – is that QSant is an at-home testing kit, which allowed customers to continue using the service during the global pandemic.
Steph
Company Specialist at Welcome to the Jungle
Benefits
- Student Loan Refinancing
- Medical, Dental and Vision Benefits For Employee and Dependents
- FSA Healthcare
- Learning and Development Programs
- Competitive Compensation Package Including Stock Options
- Referral Program
- Employee Assistance Program
- Vacation and Sick Leave Policy
- Pet Insurance
- Commuter benefits
- Employer-Paid Life, Personal Accident And Disability Insurance
- 401(k)
Company values
- Patient-Centric: We put patients first at NephroSant
- Integrity: We demonstrate integrity in our actions, fostering trust and transparency at NephroSant
- Innovation: We challenge the conventional views and drive innovation at NephroSant
Funding (1 round)
Mar 2021
$16m
SERIES A
Total funding: $16m
Leadership
Joshua Yang
(Co-founder)MBA from Stanford. Began as a Graduate Student Researcher at Department of Surgery at the UCSF School of Medicine, and at Johns Hopkins Biomedical Engineering. Was a Venture Capital Fellow at InSITE, Pear VC, and SeaX Ventures. Invests in the 21 Fund, and also serves as Co-founder & CEO of Glyphic Biotechnologies.
Minnie Sarwal
(Co-founder)A qualified MD with several degrees in medical sciences including a PhD in Molecular Genetics from Cambridge University. Has worked as a Lecturer, Professor, and a Fellow at various institutions including Guys' & St Thomas' NHS Foundation Trust, UCLA, and Stanford. Was CEO & Co-founder of Organ-i, Inc.